Immunoprecise Antibodies (IPA.V) and research institute for artificial intelligence and machine learning, Mila Institute, inked a research partnership today, according to a press release.
The two companies will collaborate to research and develop initiatives, focusing on using data and artificial intelligence to change therapeutic discovery and development.
“This partnership reflects IPA’s deep-seeded commitment to innovation. Combining our efforts with the world-renowned talent at Mila catalyzes our advancements beyond the traditional life science model, as we continue to embrace the future of therapeutic discovery to accelerate the commercialization of life-saving therapeutics,” said Dr. Jennifer Bath, chief executive officer of Immunoprecise.
The Mila Institute was founded by professor Yoshua Bengio, the co-recipient of the 2018 ACM A.M. Turing Award. The institute has been recognized for its contributions to deep learning and in the fields of language modelling, machine translation, object recognition and generative design.
“This partnership opens up an exciting opportunity for AI to tap into unexplored data sets generated by Immunoprecise’s effective and high-throughput therapeutic antibody discovery platforms, to contribute to the design of new therapeutics against life-threatening diseases that challenge humanity,” said Bengio.
Immunoprecise recently completed a feasibility study, with the help of LaPort Expert Conseil, for the design of a good manufacturing certified facility. Their partnerships with Mila and LaPort were put together by Montreal International.